Background: International evidence indicates that caretakers of pediatric leukemia patients are increasingly using complementary and alternative medicine (CAM) therapies. Such a trend has never been substantiated in the Arab world. Objective: Examine the frequency, types, modes, and reasons of CAM use among pediatric leukemia patients in Lebanon. Methods: A cross-sectional design was utilized to survey (by phone) the caregivers of all pediatric leukemia patients on the rosters of the 2 largest cancer treatment facilities in Lebanon for years [2005][2006][2007][2008][2009]. A total of 125 parents out of 175 (71.4%) completed the questionnaire, which included 3 sections: socio-demographic characteristics, clinical information and CAM use details. Data analysis employed univariate descriptive statistics, t-test, and χ 2 Results: Overall, 15.2% of respondents reported using one or more CAM therapies for their child (95% confidence interval: 8.9% to 22.0%). The main CAM therapies used included dietary supplements, prayer/spiritual healing, and unconventional cultural practices (ingesting bone ashes). CAM therapies were used for strengthening immunity (42.1%) and improving the chance of cure (21%). Pediatric users of CAM were 2 years older than nonusers and had been diagnosed with leukemia for a longer period of time (4.76 ± 3.24 vs 3.49 ± 2.38, P < .05). The percentage of males among CAM users was higher than that among nonusers (89.5% vs 56.6%, P < .05). Conclusion: Increasing awareness of both caretakers and physicians of pediatric leukemia patients on the effects and risks of CAM therapies is essential should rational, safe, and evidence-based utilization of CAM therapies be achieved.
Background
Complementary and alternative medicine (CAM) therapies are gaining public acceptance and are increasingly being used around the globe. 1 CAM therapies are used for diagnostic, therapeutic, and/or preventive health purposes to satisfy a demand not met by orthodoxy on a complementary or alternative basis. 2 CAM remedies constitute a heterogeneous group of therapies with growing popularity, including dietary supplements, multivitamin and mineral supplements, metabolic therapy, relaxation, meditation, spiritual therapy, and hypnotherapy. 2, 3 The failure of science and medicine to produce curative treatments for cancers and leukemia has enhanced the popularity of CAM use among patients, 4 with a growing evidence of increased use among pediatric leukemia patients. 5, 6 To enhance the safe and effective use of CAM among pediatric leukemia patients and help facilitate the integration of CAM therapies into a health care system, it is imperative to understand the "how" and "why" of CAM use and to investigate the potential interaction of CAM therapies with conventional treatment of pediatric leukemia.
Literature Review
Leukemia is reported to be the most common cancer among children in both developing and developed countries. [7] [8] [9] [10] [11] [12] Although cure rates are higher than 80% for children treated in modern centers, 13 treatment of pediatric leukemia is intense and usually has significant adverse effects. Caretakers of children with leukemia might resort to CAM therapies with the hope to alleviate the burden of the disease (eg, fatigue, nausea, stress) and enhance the chances of cure. 14 Despite leukemia being the most common type of pediatric cancer in Lebanon, 7 both the prevalence of use and the acclaimed therapeutic privileges for CAM therapies have never been investigated among leukemia patients in the country.
Literature reports a wide discrepancy in the prevalence of CAM utilization among both adult and pediatric leukemia patients. Nevertheless, there is evidence of a high prevalence of use among leukemia patients across most jurisdictions. 15, 16 A recent meta-analysis about the prevalence of CAM use in pediatric cancer revealed estimates that ranged between 6% and 91%. 17 This wide variation among various pediatric oncology populations is possibly because of different methodologies used across studies, the lack of a consistent defi nition of CAM and the cultural differences, which play an important role in the use of CAM. 18, 19 There appears to be a regional variation with respect to the socioeconomic determinants of CAM use among cancer patients. Whereas Asian studies report a higher likelihood of CAM use among poorly educated patients and those belonging to lower socioeconomic status, 16, 20, 21 European studies report the contrary. 4, 15 In addition, literature reports that patients with more advanced stages of cancer are more likely to be CAM users. 3, 15, 22, 23 CAM therapies are used among cancer patients for dec reasing the adverse drug reactions with conventional treatments, as a lower cost alternative to expensive conventional treatment and in hope for a miracle cure. 16, 20 Other reported reasons for use of CAM therapies among cancer patient included curing the cancer, ameliorating the undesirable effects of conventional treatments, and being able to feel some control over the cancer. 6, 14, 21, 24, 25 Despite the fact that the Middle Eastern and North African region hosts one of the fastest growing markets of CAM products in the world, 26 few data exist on the prevalence or type of use of CAM by cancer, particularly pediatric leukemia patients. The present study is the first systematic attempt in the Arab world to investigate the frequency, types, and mode of CAM use among pediatric leukemia patients and to underscore the motivators of use of these unconventional therapies.
Methods

Ethical Approval
The Institutional Research Board at the American University of Beirut, Lebanon reviewed and approved the protocol for this study. Data collection was anonymous and optional with no personal identifiers used and no incentives offered for participation. The list of patients along with all completed questionnaires was kept in a secure cabinet under lock and key with access only to the principal investigators on this study.
Target Population
All pediatric leukemia patients who were attending or have attended the largest 2 main oncology centers in Lebanon between years 2005 and 2009 were included in this study (n = 175). Inclusion criteria were (a) age of patient at the time of attending the facility between 0 and 18 years; (b) confirmed diagnosis with pediatric leukemia, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CLL); (c) interviewee conversant in Arabic or English; and (d) the patient was alive at the time of the interview.
Note that a leukemia patient was defined as a user if they consumed at least once, during the course of their treatment, one or more of the CAM therapy groups discussed above.
Survey Instrument
The questionnaire used in this study consisted of 32 questions and was divided into 3 sections: (a) sociodemographic information of caregivers and patients, including age, sex, marital status, education, income, and crowding index; (b) clinical information of patients such as age since diagnosis, family history of leukemia and other cancers, and functional impairment (assessed by Karnofsky performance status scale) 27 ; and (c) questions concerning the use of CAM (if any) since diagnosis with leukemia, the type, the purpose of use and perceived benefits, and whether CAM was used as a complementary or alternative approach to the conventional treatment of pediatric leukemia. The survey questionnaire was reviewed and modified by an expert panel. The final version of the questionnaire was pilot tested on 4 leukemia patients. Minor modifications to enhance clarity were incorporated.
Data Collection
A database including the names and contact phone numbers of all pediatric leukemia patients was compiled from the 2 facilities. The database was cleaned to ensure that the patients met the inclusion criteria and avoid double counting (should the same patient have attended the 2 facilities over the period of the analysis). A trained interviewer called the patients' phone number and invited the main caregiver for the child with pediatric leukemia to participate in this study. After explaining the study and its objectives, an oral consent was sought. Caregivers were assured that declining participation will not affect by any means the care for their children. Although most of the questions had multiple choice answers, caregivers were encouraged to answer freely should their reply not be listed within the choices.
Data Analysis
Descriptive statistics, including frequencies and means, were reported for the sociodemographic and clinical variables considered in this study. Differences between groups were tested with Fisher's exact, χ 2 , and independent t tests. A P value of .05 or less was set to detect significant differences. All tests were performed using SPSS software. 28
Results
Out of 175 eligible pediatric leukemia patients identified from both health centers, a total of 50 patients were lost either because (a) they could not be reached at the phone number provided by the health care institution (n = 32) or (b) they did not consent to participating in the study (n = 18). Therefore, 125 patients participated in the study yielding an overall response rate of 71.5%. All of these 125 questionnaires were included in the analysis.
Sociodemographic and Clinical Characteristics
The sociodemographic characteristics of caregivers are presented in Table 1 . Most of the questionnaires were answered by the mothers (83.2%), who were mainly housewives (73.6%). Parents belonged to various socioeconomic levels as indicated by the distribution of their education, income, and crowding index.
Patients' clinical characteristics are given in Table 2 . Mean age of the patients was 9.5 ± 4.1 years. At diagnosis, patients' age ranged from 6 months to 17 years with a mean of 5.8 years. The sample of patients consisted of more males (61%).
When family history of cancers was investigated, 14% of patients had a family history of pediatric leukemia and 30% had a history of other cancers. At the time of the study, 77% of the patients were receiving at least one kind of conventional treatment (chemotherapy, radiation, or any kind of medication). According to the Karnofsky performance status, 30.4% of patients were able to perform their activities normally, 28% were able to carry normal activities with slight recognition of symptoms, 25% of the patients were able to carry on normal activities with increased effort and a slight recognition of symptoms whereas 21% of the patients were not able to carry on normal activities. Two patients were reported to be completely disabled and needed continuous assistance.
CAM Use
The characteristics of the use of CAM are shown in Table 3 . Out of 125 parents, 19 reported using one or more CAM therapy for their child (15.2%, 95% confidence interval = 8.9% to 22.0%). The types of CAM therapies used were mainly dietary supplements (blackseed, 28.5%; bone ash dissolved in water, 19%; green tea; holy water; honey and carob syrup mixture; and rosemary, 4.7% each). In addition 28.6% of parents reported using prayer and spiritual healing; in few cases, the use of more than one type of CAM therapy was reported. Among parents who did not use any type of CAM for their children, 15.1% indicated consideration for using CAM in the future. When asked about the main reason for not using CAM, 40% of parents answered that the "doctor did not prescribe it" and a quarter of respondents did not believe in CAM use. Among users of CAM therapies, less than a third asked their doctor about the therapies, and most of them adhered to the treatment prescribed by their doctors (89.5%).
Although close to two thirds of interviewed parents did not research the CAM therapy that they used for the children and three quarters were doubtful about the effect of use, none acknowledged that their children experienced any negative side effects. The most common reason reported for using CAM therapies was "strengthening immunity" (42.1%). Other reported reasons included improving the chance of cure (21%), detoxification (10%), minimizing the pain (11%), lack of trust in conventional medicine (11%), and belief that CAM stops the progression of the disease (5%).
Characteristics Associated With CAM Use
There were no significant differences between the users and nonusers of CAM for age, education, income of the parent, and family history of pediatric leukemia. Among the patient characteristics, age, time since diagnosis, sex distributions, and family history of leukemia were significantly different between users of CAM and nonusers. Users of CAM were 2.36 years older than nonusers and had been diagnosed for cancer for a longer period of time (4.76 ± 3.24 vs 3.49 ± 2.38, P < .05). The percentage of males among users of CAM was significantly higher than among nonusers (89.5% vs 56.6%, P < .05). Patients with a family history of leukemia were more likely to use CAM therapies when compared with patients without a family history (31.6% vs 9.4%, P < .05; Table 4 ).
Discussion
To the authors' knowledge, this study is the first report about the use of CAM therapies among children with pediatric leukemia in the Arab world. Our findings show that 15.4% of pediatric leukemia patients have used CAM therapies since their diagnosis with the disease. This percentage of users is comparable with a recent study by Clerici et al 24 who showed that 12.4% of children suffering from neoplastic diseases in Italy used at least one kind of CAM therapy since their diagnosis. However, this is lower than estimates in other studies carried out in the United States, 29 Turkey, 30 and Malaysia. 6 Methodological, cultural, and definitional differences might explain this variation. 19 Although parents of a child with cancer want to help their child recover from the disease by providing CAM therapies, the young age at which pediatric leukemia is usually diagnosed (2-5 years) could have limited parents' intervention. In addition, the lower prevalence of CAM use could potentially be attributed to the relatively good prognosis in pediatric leukemia with current treatment regimens resulting in event-free survival rates for childhood ALL approaching or exceeding 80%. 31 The main CAM therapies used in our sample population was blackseed and spiritual healing followed by bone ash dissolved in water. Blackseed is the common name for Nigella sativa L. (Ranunculaceae family) seeds. This seed has been used for thousands of years as a spice and food preservative, as well as a protective and curative remedy for numerous disorders. 32 In Lebanon and other parts of the Middle East, there is a common Islamic belief that blackseed has curative powers, but cannot prevent aging or death. Blackseed is also identified as the curative black cumin in the Holy Bible. 33 Many studies have been conducted over the past 2 decades to investigate the potential effects of N sativa seed extracts on various body systems in vitro or in vivo, including cancer chemopreventive potential and possible reduction in the toxicity of standard antineoplastic drugs. 34 Spiritual healing (eg, prayer, lighting candles in churches, and consulting with religious authorities) was reported by 32% of users. This prevalence is higher than what was recently observed in Turkey (18.9%) but comparable with the results reported in Taiwan (40%) and Montreal (32%). 35 These therapies have the advantage of being inexpensive and easy to use. They also do not threaten the parents or patients. 36 When considering spiritual healing and prayer as a form of CAM, it is important to differentiate it from the "obligatory" and/or "standard prayers." Moreover, the spiritual healing and prayer in that case refers to the "formal or informal practices" rooted from the person's personal desire rather than a compulsory act. With this type of CAM, survival benefits are not guaranteed; however, there appears to be positive association between religiousness/spirituality, and higher well-being and positive effect, as well as a negative association with depressive and anxiety symptoms. 37 In our study population, 19% of CAM users gave their children bone ash obtained from human bones and then dissolved in warm water. This preparation was never investigated by researchers. It relies on ancient systems of healing that are based on concepts in human philosophy rather than scientific knowledge. All parents denied any side effects of the CAM therapy used, which, similar to other studies, reflects the perception of some parents that the CAM used is safe and effective. 30, 38 Our results indicated that strengthening immunity and improving the chance of cure were the main reasons behind the use of CAM. This finding is in accordance with the results of other studies in Germany 25 and in Canada. 39 In our study, the dissatisfaction with conventional medicine does not seem to be an important driver for CAM use, with only 11% of survey respondents indicating disbelief in conventional medicine as a cure for cancer as a reason for use of CAM. This finding is comparable to that of Laengler et al. 25 In addition to assessing the reasons for CAM use in pediatric cancer patients, we have investigated the main barriers for CAM use among nonusers. Our results show that "the doctor did not prescribe it" was the main barrier (40%) followed by "I do not believe in it" (25.7%). These results indicate that trust in conventional medicine is very prevalent among parents of leukemic children, probably because of the good prognosis with the current conventional therapies.
Our results indicated that less than a third (32%) of CAM users consulted with their doctors prior to use. This is in accordance with studies indicating that CAM users rarely discuss use with a doctor. 36, 40 Other studies, however, reported much higher rates of communication between caregivers of children with cancer and their treating physician. 25, 39 The reluctance of patients to disclose the use of CAM therapies to their treating physician unearthed in this study is worrisome and warrants further investigation. In addition, pediatric oncologists could possibly be trained to skillfully probe patients on the CAM therapies.
Among patient characteristics, our results indicated that users of CAM were around 2 years older than nonusers and had been diagnosed with leukemia for a longer period of time. This finding could be attributable to the fact that older children might be more accepting to the use of CAM therapies, in addition, the longer the conventional treatment lasts, the more parents feel that they need to resort to other types of treatment that could help their child recover faster. Note that this finding is consistent with other studies of CAM use among pediatric cancer patients that showed that the use of CAM increases with the age of the child and with the time since the cancer diagnosis. 30, 41 In addition, family history of leukemia was a significant determinant of CAM use; families that might have had a previous painful experience with cancer appear to be more accepting of nonconventional therapies.
From a health systems perspective, it is important to note that the treatment of cancer and leukemia is one of the chronic conditions eligible for full subsidization by the Lebanese Ministry of Public Health for the duration of the treatment. 42 This added to the availability of state-of-the-art treatment facilities and an overabundance of medical specialists in Lebanon remove important barriers to the utilization of cancer treatment in Lebanon related to affordability and accessibility of conventional treatment. Assessment of CAM use among leukemia patients might reveal a higher prevalence of use in other countries in the EMR region, depending on the degree of subsidization and accessibility to conventional treatment.
The study has nevertheless unearthed concerns with the level of awareness of parents and specialists regarding the safe use of complementary therapy alongside conventional treatment. This could be attributed to the lack of national database of CAM therapies in the local market and the absence of any public education in the field; except for a number of TV programs that promote inaccurate claims about therapeutic characteristics of certain CAM products. It is also important to note that medical education in Lebanon does not incorporate specific modules on CAM therapies and is solely focused on conventional treatment modalities.
A number of limitations in this study warrant mention. First, the current study might have underestimated the prevalence of CAM use since all surveyed parents had their children on the roster of a cancer treatment center, thus might have a bias toward conventional treatment. Second, since more than three quarters of respondents had their children undergoing conventional therapy at the time of the survey, some parents might fear, amid the researchers' assurances, reporting the use of unconventional CAM therapies. Third, we cannot ascertain the absence of a recall bias in self-reports concerning CAM use. Fourth, although a very clear definition of CAM therapies was shared with parents over the phone, we could not ensure that the interviewed parents had a good understanding of what is meant by CAM.
Conclusion
Sampling and health systems characteristics might have mitigated the prevalence of CAM use among pediatric leukemia patients in Lebanon. Nevertheless, this study ascertained that CAM therapies are being used by a proportion of pediatric leukemia patients in Lebanon, including some worrisome and potentially harmful practices. Health care providers are seldom consulted on the safe use of CAM therapies. Building on the findings of this study, future research programs could run a regional multicountry study on a larger sample of pediatric leukemia patients to investigate the prevalence and characteristics of use of CAM therapies. It is recommended that future studies be supplemented by a qualitative component to investigate the barriers and facilitators of communication between parents and providers regarding the safe use of CAM therapies.
The reported use of unconventional and potentially harmful CAM therapies, coupled with the poor communication between users and physicians with respect to CAM use, suggest that the government should work collaboratively with professional bodies, academic institutions and consumer protection organizations to initiate a policy discourse on the means to enhance public awareness on the safe and rational use of CAM and improving the knowledge of providers on evidence-based utilization of CAM therapies. There appears to be a long way to go before CAM therapies could be incorporated into the health care system in Lebanon.
Until then, the onus remains on pediatric leukemia patients and providers to ensure safe use of CAM therapies.
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